Immune System Disorder (Healthy Volunteer) Clinical Trial
Official title:
A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalating Study to Examine the Safety and Tolerability of Multiple Doses of KD025 (Formerly Called SLX-2119) in Healthy Male and Post- Menopausal Female Subjects
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of multiple oral doses and regimens of KD025 in healthy male and post-menopausal female participants.
Up to approximately 37 days including safety follow up period of 30 days after participant is treated with the last dose of study drug. ;